TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12740532

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10994885

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) at a dose of 0.1 mg/kg for 29 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8851268

Group type: EXPERIMENTAL
Intervention: Taprostene administered as a continuous intravenous infusion from 2 hours before until 8 or 24 hours after angioplasty.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group received a combination of 330 mg aspirin and 75 mg dipyridamole.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Taprostene patients experienced 3 early reocclusions up to 72 hours after the procedure and 1 late reocclusion within 3 months.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (aspirin and dipyridamole).
Number of subjects: 19
Study: 10147024

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminoglycoside/antianaerobe combination regimens
Number of subjects: 0
Study: 6337200

Group type: EXPERIMENTAL
Intervention: Aspirin (10 gr twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30470592

Group type: EXPERIMENTAL
Intervention: WHELD intervention
Number of subjects: 549

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 549
Study: 29651981

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200 mg/day, or up to 400 mg/day for women on combined oral contraceptives)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 276
Study: 27302207

Group type: EXPERIMENTAL
Intervention: Saccadic Eye Movement (SEM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pursuit Eye Movement (PEM)
Number of subjects: 104
Study: 24739593

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (combination therapy)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Aspirin alone (monotherapy)
Number of subjects: 574
Study: 22030240

Group type: EXPERIMENTAL
Intervention: Quarterly individual lifestyle counseling visits by a nurse and a dietitian
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 398
Study: 19837920

Group type: EXPERIMENTAL
Intervention: ID fat infusion with orlistat
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ID sodium oleate (C18:1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ID sodium caprylate (C8:0)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ID sodium oleate with dexloxiglumide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ID fat or sodium oleate
Number of subjects: 34

Group type: COMPARATOR
Intervention: ID sodium caprylate
Number of subjects: 34
Study: 17389559

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral contraceptive
Number of subjects: 34
Study: 16270634

Group type: EXPERIMENTAL
Intervention: Recombinant human FXIII A2 (rFXIII) at doses of 10 or 25 U/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11801583

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 4 mg/kg/day
Number of subjects: 312

Group type: COMPARATOR
Intervention: Conventional amphotericin
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 312
Study: 9973872

Group type: EXPERIMENTAL
Intervention: Borg's Scale
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body Part Discomfort Rating
Number of subjects: 20
Study: 7754475

Group type: EXPERIMENTAL
Intervention: Minocycline (Mynocine) 100 mg per day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Roxithromycin (Rulid) 300 mg per day
Number of subjects: 124
Study: 2407004

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at various dosages (40 mg/m2, 80 mg/m2, 120 mg/m2, 180 mg/m2, 220 mg/m2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rescue use of 15-deoxyspergualin (DSG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined use of 15-deoxyspergualin (DSG) with other agents
Number of subjects: 34
Study: 7426191

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30655198

Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SUX) for intubation with no further NMB administered
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cisatracurium (group CIS) for intubation and maintenance NMB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SUX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cisatracurium (group CIS)
Number of subjects: 100
Study: 27890344

Group type: EXPERIMENTAL
Intervention: Safe@Last program
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 1177
Study: 26717354

Group type: EXPERIMENTAL
Intervention: Sargassum extract 250 μg/mL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sargassum extract 500 μg/mL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no Sargassum extract)
Number of subjects: 11
Study: 24050803

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 7447

Group type: COMPARATOR
Intervention: Control group (low-fat diet education)
Number of subjects: 7447
Study: 20574413

Group type: EXPERIMENTAL
Intervention: Interval training program (work:rest ratio of 1:1, 8 weeks, 45-60 minutes, 60-79% heart rate maximum)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Continuous training program (8 weeks, 45-60 minutes, 60-79% heart rate maximum)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (sedentary during the 8 weeks)
Number of subjects: 357
Study: 19639620

Group type: EXPERIMENTAL
Intervention: 1,550 nm Er:Glass fractional laser (3 treatments with 6-week intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CROSS method (2 treatments every 12 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1,550 nm Er:Glass fractional laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: CROSS method
Number of subjects: 20
Study: 17967602

Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 36489
Study: 15281539

Group type: EXPERIMENTAL
Intervention: FNB and selective ONB (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FNB (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo FNB (Group 3)
Number of subjects: 90
Study: 11903417

Group type: EXPERIMENTAL
Intervention: 2 mg glimepiride
Number of subjects: 2224

Group type: EXPERIMENTAL
Intervention: 1 mg glimepiride
Number of subjects: 2224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2224
Study: 9446434

Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 119
Study: 8432776

Group type: EXPERIMENTAL
Intervention: Low dose alpha human atrial natriuretic peptide (ANP) infusion (2.5 pmol/kg.min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 8
Study: 3481429

Group type: EXPERIMENTAL
Intervention: Alginate conjugated Dermatophagoides pteronyssinus extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29212825

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (SBP target <120 mmHg)
Number of subjects: 14094

Group type: COMPARATOR
Intervention: Standard blood pressure lowering (SBP target <140 mmHg)
Number of subjects: 14094
Study: 27426932

Group type: EXPERIMENTAL
Intervention: 7.44 mg total macular carotenoid
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 13.13 mg total macular carotenoid
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 27.03 mg total macular carotenoid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 28
Study: 24827969

Group type: EXPERIMENTAL
Intervention: recombinant human bone morphogenetic protein‐7 (rhBMP‐7) along with intramedullary Kirschner (K)‐wire fixation and autologous bone grafting
Number of subjects: 20

Group type: COMPARATOR
Intervention: K wire and grafting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 20
Study: 22606862

Group type: EXPERIMENTAL
Intervention: 35 days horizontal bed rest
Number of subjects: 10
Study: 20155235

Group type: EXPERIMENTAL
Intervention: Experimental schools (Tier 1 Program of Project P.A.T.H.S.)
Number of subjects: 6785

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 6785
Study: 17650364

Group type: EXPERIMENTAL
Intervention: Process simulation only
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Outcome simulation only
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Process-plus-outcome simulation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Distractor control condition
Number of subjects: 146
Study: 16622454

Group type: EXPERIMENTAL
Intervention: Docetaxel 80 mg m‐2 and epirubicin 75 mg m‐2 (ED)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Docetaxel 100 mg m‐2 (D)
Number of subjects: 51
Study: 12955305

Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg oxycodone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 mg morphine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11763004

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg daily for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study: 8989002

Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg/kg bolus followed by 1 mg.kg-1.h-1 continuous infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralipid (placebo)
Number of subjects: 60
Study: 8433358

Group type: EXPERIMENTAL
Intervention: Cognitive distraction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study: 2887529

Group type: EXPERIMENTAL
Intervention: mesterolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31538405

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injection of 1 mL 0.5% bupivacaine with 3 cycles of pulsed radiofrequency of the DRG for 180 seconds (LPRF group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transforaminal epidural injection of 1 mL 0.5% bupivacaine (LA group)
Number of subjects: 50
Study: 29309313

Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation (AMPS) applied twice a week for 4 weeks using a commercial medical device (Gondola) delivering mechanical pressure in four areas of feet.
Number of subjects: 30

Group type: COMPARATOR
Intervention: AMPS SHAM (placebo) applied twice a week for 4 weeks delivering subliminal stimulus.
Number of subjects: 30
Study: 26343552

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with adjunctive use of an essential-oil (EO)-based oral rinse for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone with water rinse for 30 days
Number of subjects: 60
Study: 26247702

Group type: EXPERIMENTAL
Intervention: Same gender companion
Number of subjects: 216

Group type: COMPARATOR
Intervention: Opposite gender companion
Number of subjects: 216
Study: 22961571

Group type: EXPERIMENTAL
Intervention: More Intensive (MI) regimen
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: No Change (NC) regimen
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Less Intensive (LI) regimen
Number of subjects: 1606
Study: 20830647

Group type: EXPERIMENTAL
Intervention: Brief emotion-focused psychotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Client-centred psychotherapy
Number of subjects: 34
Study: 18458209

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention modeled on the Baby‐Friendly Hospital Initiative by WHO and UNICEF
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17046
Study: 16740868

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions
Number of subjects: 15
Study: 12700501

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopy for diagnosis
Number of subjects: 0
Study: 11194383

Group type: EXPERIMENTAL
Intervention: Desflurane and remifentanil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sevoflurane and remifentanil
Number of subjects: 62
Study: 9369828

Group type: EXPERIMENTAL
Intervention: Single-dose cefotetan (2 gm intravenous)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Multiple-dose cefotetan (2 gm intravenous every 12 hours for a minimum of 48 hours)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Single-dose cefotetan
Number of subjects: 109

Group type: COMPARATOR
Intervention: Multiple-dose cefotetan
Number of subjects: 109
Study: 31855086

Group type: EXPERIMENTAL
Intervention: HL301 (600 mg/day)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Umckamin (333 mg/day)
Number of subjects: 246
Study: 31720257

Group type: EXPERIMENTAL
Intervention: Resistant starch (13.5 g Hi-Maize 260 daily for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28409364

Group type: COMPARATOR
Intervention: CL + D
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RL and RL + D
Number of subjects: 32
Study: 26271080

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 3349

Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication
Number of subjects: 3349

Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication (mediator)
Number of subjects: 3349
Study: 23739960

Group type: EXPERIMENTAL
Intervention: Continuous flash suppression (CFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher contrast targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowest contrast target rendered invisible by CFS
Number of subjects: 0
Study: 21411598

Group type: EXPERIMENTAL
Intervention: Vi-rEPA
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (EPI vaccines alone)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Vi-rEPA and Hib-TT
Number of subjects: 301
Study: 18651193

Group type: EXPERIMENTAL
Intervention: Yoga use for health
Number of subjects: 31044
Study: 15988081

Group type: COMPARATOR
Intervention: Combined treatment with Depakin (30 mg/kg) and Mexidol (5 mg/kg) in children with generalized epilepsy.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monotherapy with Mexidol (5 mg/kg) in children with first episode of febrile seizures.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group treated only with Depakin in children with generalized epilepsy.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group without any treatment in children with first episode of febrile seizures.
Number of subjects: 220
Study: 12184060

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Eprosartan (600 mg/day)
Number of subjects: 58
Study: 10491894

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole 10 mg every 8 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral aspirin 300 mg every 24 hours
Number of subjects: 60
Study: 8708728

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) 40 mg/m2
Number of subjects: 232

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, and vincristine (ABV) regimen
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 232
Study: 1768819

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 16
Study: 6753911

Group type: EXPERIMENTAL
Intervention: Captopril 37.5 mg, 75 mg or 150 mg/day for 7 weeks
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Captopril plus placebo
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Captopril plus hydrochlorothiazide 25 mg twice daily
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 475
Study: 30877851

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with D-cycloserine augmentation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) with placebo augmentation
Number of subjects: 136
Study: 28712074

Group type: EXPERIMENTAL
Intervention: 12.5 mg/day SHP465 MAS
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: 37.5 mg/day SHP465 MAS
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 26825824

Group type: EXPERIMENTAL
Intervention: Continuous low-dose oral cyclophosphamide 50 mg and methotrexate 2.5 mg (maintenance arm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation arm (control)
Number of subjects: 60
Study: 24956453

Group type: EXPERIMENTAL
Intervention: GA with a single‐injection TPVB and placebo paravertebral infusion
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: GA with a continuous TPVB
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standardized GA
Number of subjects: 180
Study: 22103956

Group type: EXPERIMENTAL
Intervention: 9-week group intervention including parenting, adolescent coping, and conjoint family sessions
Number of subjects: 516

Group type: COMPARATOR
Intervention: Low-dosage control group workshop
Number of subjects: 516
Study: 19924281

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(B)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(A)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: RTS,S/AS vaccines (pooled)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 191
Study: 17207676

Group type: EXPERIMENTAL
Intervention: Abdominal brace technique
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transversus abdominis activation during brace
Number of subjects: 8

Group type: COMPARATOR
Intervention: Abdominal hollowing technique
Number of subjects: 8
Study: 15211082

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Teicoplanin and Vancomycin
Number of subjects: 124
Study: 11581040

Group type: COMPARATOR
Intervention: Topical anesthesia without intravenous sedatives
Number of subjects: 19250

Group type: COMPARATOR
Intervention: Injection anesthesia without intravenous sedatives
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with intravenous sedatives
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Injection anesthesia with intravenous sedatives
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (alone)
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with opiates)
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with sedatives)
Number of subjects: 19250

Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with opiates and sedatives)
Number of subjects: 19250
Study: 9636865

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (100 mg once daily for 14 days)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Fluconazole capsules (100 mg once daily for 14 days)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (100 mg twice daily for 7 days)
Number of subjects: 244
Study: 8179396

Group type: EXPERIMENTAL
Intervention: Dideco autotransfusion system
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sorin autotransfusion system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 3276670

Group type: EXPERIMENTAL
Intervention: Desipramine in combination with methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30446894

Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*1 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*3 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: CYP3A5*1/*1 vs CYP3A5*1/*3
Number of subjects: 0

Group type: COMPARATOR
Intervention: CYP3A5*1/*1 vs CYP3A5*3/*3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed graft functioning
Number of subjects: 0
Study: 28566364

Group type: EXPERIMENTAL
Intervention: Leaflet preservation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Leaflet resection
Number of subjects: 88
Study: 25661282

Group type: EXPERIMENTAL
Intervention: suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 23426612

Group type: EXPERIMENTAL
Intervention: Mask Positive Pressure Ventilation (PPV)
Number of subjects: 29
Study: 21185737

Group type: EXPERIMENTAL
Intervention: Video Doctor plus Provider Cueing intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 18652757

Group type: EXPERIMENTAL
Intervention: V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide)
Number of subjects: 126

Group type: COMPARATOR
Intervention: V80 (80 mg valsartan)
Number of subjects: 126
Study: 17068384

Group type: EXPERIMENTAL
Intervention: MALDI-TOF protein profiling
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (29 controls)
Number of subjects: 107
Study: 12664247

Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam (Dz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 0